1. Home
  2. HXL vs RNA Comparison

HXL vs RNA Comparison

Compare HXL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hexcel Corporation

HXL

Hexcel Corporation

HOLD

Current Price

$79.08

Market Cap

6.0B

Sector

Industrials

ML Signal

HOLD

Logo Avidity Biosciences Inc.

RNA

Avidity Biosciences Inc.

HOLD

Current Price

$13.22

Market Cap

227.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXL
RNA
Founded
1946
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
227.6M
IPO Year
1994
2025

Fundamental Metrics

Financial Performance
Metric
HXL
RNA
Price
$79.08
$13.22
Analyst Decision
Buy
Buy
Analyst Count
11
20
Target Price
$81.73
$69.26
AVG Volume (30 Days)
1.1M
1.1M
Earning Date
04-20-2026
01-01-0001
Dividend Yield
0.89%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,893,900,000.00
N/A
Revenue This Year
$10.20
$88.12
Revenue Next Year
$12.65
$18.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$45.28
$11.95
52 Week High
$95.22
$73.06

Technical Indicators

Market Signals
Indicator
HXL
RNA
Relative Strength Index (RSI) 38.06 9.41
Support Level $76.70 $13.06
Resistance Level $79.20 $72.75
Average True Range (ATR) 2.44 0.62
MACD -0.42 1.88
Stochastic Oscillator 21.16 37.39

Price Performance

Historical Comparison
HXL
RNA

About HXL Hexcel Corporation

Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in the commercial aerospace, defense, and high-performance automotive markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.

About RNA Avidity Biosciences Inc.

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Share on Social Networks: